Day One Biopharmaceuticals filed an 8-K on November 4, 2025, primarily to announce the release of financial results and corporate updates for the quarter ended September 30, 2025.
Financial Performance & Guidance The company reported strong commercial execution for OJEMDA (tovorafenib). Q3 2025 Net Product Revenue reached $38.5M, marking 15% sequential growth. Year-to-date revenue totaled $102.6M, already surpassing full-year 2024 results. While the company posted a net loss of $19.7M, R&D expenses decreased YoY ($31.4M vs $33.6M). The company raised its FY 2025 net product revenue g
...